» Articles » PMID: 34014998

Facilitators and Barriers of 2-1-1 HIV Pre-exposure Prophylaxis

Overview
Journal PLoS One
Date 2021 May 20
PMID 34014998
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

An alternative strategy for men who have sex with men (MSM) experiencing challenges with daily HIV pre-exposure prophylaxis (PrEP) includes 2-1-1 dosing. Understanding 2-1-1 PrEP facilitators and barriers, especially during the SARS-CoV-2 pandemic, may guide researchers and healthcare providers in future studies and clinical preparedness. We conducted a national cross-sectional study of MSM in the US who had taken 2-1-1 PrEP to examine facilitators and barriers of this on-demand PrEP dosing option. With the shelter-in-place orders in March 2020, this study was adapted to include questions on how the SARS-CoV-2 pandemic affected participants' PrEP use. A total of 140 individuals participated in the survey, 106 of which completed questions pertaining to the SARS-CoV-2 pandemic. The most common reasons for switching from once-daily to 2-1-1 PrEP included having sex less frequently (63.6%) and wanting to take fewer pills (46.4%). Participants reported high medication adherence based on each component of 2-1-1 PrEP dosing (>84%). The most common barriers with 2-1-1 PrEP dosing included unplanned sexual encounters resulting in missing the double-dose pre-sex (43.6%) and trouble remembering doses post-sex (29.3%). Facilitators of the 2-1-1 PrEP dosing strategy included reductions in sexual encounters (63.6%), preference to take fewer pills (46.4%), need to reduce cost (22.1%), and desire to reduce side effects (19.3%). Challenges to receiving PrEP services during the pandemic included obtaining laboratory testing (25.5%) and PrEP refills (either receipt of a refill authorization from a healthcare provider or processing of a refill from the pharmacy) (18.9%). 2-1-1 PrEP is an effective HIV prevention method; therefore, understanding facilitators and barriers of this dosing strategy can result in continuous provision of HIV prevention efforts, particularly during a pandemic.

Citing Articles

Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.

Islek D, Sanchez T, Glick J, Jones J, Rawlings K, Sarkar S JMIR Public Health Surveill. 2024; 10():e62801.

PMID: 39536313 PMC: 11602762. DOI: 10.2196/62801.


Reconciling advantages and difficulties: knowledge and perceptions of event-driven PrEP among young people.

Deus L, Ferraz D, Santos L, Grangeiro A, Dourado I, Couto M Rev Saude Publica. 2024; 58(suppl 1):13s.

PMID: 39417509 PMC: 11573368. DOI: 10.11606/s1518-8787.2020054005729.


Perspectives and Factors Related to Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: A Mixed-Methods Study on the Role of History of PrEP Use.

Ma J, Soberano Z, Stamp B, Rosso M, Hightow-Weidman L, Powers K J Assoc Nurses AIDS Care. 2024; 35(6):530-543.

PMID: 39208418 PMC: 11529780. DOI: 10.1097/JNC.0000000000000489.


Gay and Bisexual Men's Perceptions about a Potential HIV Vaccine within a Post-COVID-19 Era: A Qualitative Study.

DAngelo A, Dearolf M, MacMartin J, Elder M, Nash D, Golub S AIDS Behav. 2024; 28(11):3787-3800.

PMID: 39122906 DOI: 10.1007/s10461-024-04450-8.


Correlates of oral pre-exposure prophylaxis cessation among men who have sex with men in China: implications from a nationally quantitative and qualitative study.

Liu Y, Wei S, Cheng Z, Xian Y, Liu X, Yang J BMC Public Health. 2024; 24(1):1765.

PMID: 38956521 PMC: 11221119. DOI: 10.1186/s12889-024-19182-6.


References
1.
Cottrell M, Yang K, Prince H, Sykes C, White N, Malone S . A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. 2016; 214(1):55-64. PMC: 4907409. DOI: 10.1093/infdis/jiw077. View

2.
Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

3.
Siegler A, Mayer K, Liu A, Patel R, Ahlschlager L, Kraft C . Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program. Clin Infect Dis. 2018; 68(3):501-504. PMC: 6336909. DOI: 10.1093/cid/ciy529. View

4.
Sewell W, Powell V, Mayer K, Ochoa A, Krakower D, Marcus J . Nondaily Use of HIV Preexposure Prophylaxis in a Large Online Survey of Primarily Men Who Have Sex With Men in the United States. J Acquir Immune Defic Syndr. 2020; 84(2):182-188. PMC: 7228850. DOI: 10.1097/QAI.0000000000002332. View

5.
Marcus J, Hurley L, Hare C, Nguyen D, Phengrasamy T, Silverberg M . Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016; 73(5):540-546. PMC: 5424697. DOI: 10.1097/QAI.0000000000001129. View